Oxford Immunotec Global (NASDAQ:OXFD) Stock Rating Lowered by Zacks Investment Research

Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other research analysts have also recently weighed in on OXFD. BidaskClub cut shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 26th. ValuEngine cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, July 23rd. Finally, TheStreet cut shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research note on Monday, July 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company’s stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and a consensus target price of $18.00.

OXFD stock traded up $0.17 on Thursday, hitting $13.21. The company had a trading volume of 149,349 shares, compared to its average volume of 185,511. Oxford Immunotec Global has a 12-month low of $11.88 and a 12-month high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average of $13.49. The company has a market capitalization of $343.44 million, a PE ratio of 18.43 and a beta of 0.33.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company had revenue of $14.79 million for the quarter, compared to analysts’ expectations of $13.74 million. During the same quarter last year, the company posted ($0.40) earnings per share. The firm’s quarterly revenue was up 26.6% on a year-over-year basis. Analysts anticipate that Oxford Immunotec Global will post -0.24 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Aperio Group LLC bought a new stake in shares of Oxford Immunotec Global during the 2nd quarter valued at $42,000. BNP Paribas Arbitrage SA raised its position in shares of Oxford Immunotec Global by 59,988.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock valued at $93,000 after purchasing an additional 5,399 shares during the period. Squarepoint Ops LLC raised its position in shares of Oxford Immunotec Global by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock valued at $247,000 after purchasing an additional 5,120 shares during the period. Campbell & CO Investment Adviser LLC raised its position in shares of Oxford Immunotec Global by 15.0% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock valued at $343,000 after purchasing an additional 3,255 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of Oxford Immunotec Global by 972.3% during the 1st quarter. Acadian Asset Management LLC now owns 33,969 shares of the company’s stock valued at $586,000 after purchasing an additional 30,801 shares during the period. Institutional investors and hedge funds own 91.19% of the company’s stock.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Article: Gap Down Stocks

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.